AstraZeneca to Develop Astex PKB Inhibitors; Compounds May Rescue EGFR-Drug Response | GenomeWeb

In an agreement with AstraZeneca, UK-based Astex Therapeutics will provide the pharmaceutical giant with a set of drug candidates that inhibit protein kinase B, and may well be capable of recovering tumor response to EGFR inhibitors in patients for whom drugs like Genentech's Tarceva or AstraZeneca's Iressa are no longer effective.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.